Drug intelligence / Profile preview

AD12

Development stage: Preclinical
Lead developer: ADvantage Therapeutics

Overview

AD12 is a preclinical-stage therapeutic candidate being developed by ADvantage Therapeutics for the treatment of Alzheimer's disease. While specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed, it is part of a pipeline focused on immunotherapeutic approaches to neurodegeneration. The company's lead program, AD04, is an immunomodulator designed to stimulate the innate immune system, and AD12 represents a follow-on or complementary program within their portfolio of therapies for neurodegenerative conditions.

Beyond the preview

Go deeper on AD12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD12.

Explore the full profile